A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT07140016 · RECRUITING

Trial details

NCT number: NCT07140016
Sponsor: Astellas Pharma Global Development, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Start date: 2025-09-22
Primary completion: 2029-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.